NASDAQ:BCRX

Biocryst Pharmaceuticals Stock Predictions

etoro logo Buy BCRX
*Your capital is at risk
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

BCRX Prediction Chart

BCRX Predictions History

Latest community submissions for BCRX.
Predictor Target Session Target Price Result Direction Accuracy Score
Jun 11, 2020 $3.69 -12.56% $4.23 X 87.34% 1
JS JS Pro
Jun 8, 2020 $3.98 -9.55% $4.40 X 90.45% 0
Jun 8, 2020 $4.80 +9.09% $4.40 X 90.91% 1
JS JS Pro
Jun 1, 2020 $4.42 -5.76% $4.69 X 94.24% 0
Desmond Lew Desmond Lew @DesmondLew.162288
Jun 1, 2020 Bullish $4.69 X 1
Jun 1, 2020 Bullish $4.69 X 1
JS JS Pro
Apr 20, 2020 $3.18 -8.36% $3.47 X 91.64% 0
تراحيب العتيبي تراحيب العتيبي @D8AAD8B1D8A7D8ADD98AD8A8D8A7D984D8B9D8AAD98AD8A8D98A.135728
Apr 20, 2020 $7.40 +113.26% Unrealistic Excluded from avg $3.47 X 0.00% 1
JS JS Pro
Apr 15, 2020 $2.68 -0.74% $2.70 X 99.26% 4
Nov 21, 2019 $2.06 -8.04% $2.24 X 91.96% 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for BCRX with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT BIOCRYST PHARMACEUTICALS
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE